Treating rotator cuff conditions

Abstract

This document provides methods and materials related to treating rotator cuff conditions (e.g., rotator cuff tendonitis or rotator cuff injuries such as partial rotator cuff tears). For example, methods and materials for using BMP-5 polypeptides to treat rotator cuff conditions as well as methods and materials for using inhibitors of SIRT6, SIRT7, and/or HDAC10 polypeptide expression or activity to treat rotator cuff conditions are provided.

1 . A method for treating a mammal having a rotator cuff condition, wherein said method comprising injecting a composition comprising a BMP-5 polypeptide into a rotator cuff region of said mammal, wherein injection of said composition reduces or reverses tendon degeneration, enhances tendon healing, or increases tendon strength. 
     
     
         2 . The method of  claim 1 , wherein said mammal is a human. 
     
     
         3 . The method of  claim 1 , wherein said rotator cuff condition is a rotator cuff condition wherein a rotator cuff tendon is partially torn. 
     
     
         4 . (canceled) 
     
     
         5 . The method of  claim 1 , wherein said rotator cuff condition is rotator cuff tendonitis. 
     
     
         6 . The method of  claim 1 , wherein said injection is an intra-articular injection into a joint space. 
     
     
         7 . (canceled) 
     
     
         8 . The method of  claim 1 , wherein said injection is a direct injection into a damaged tendon. 
     
     
         9 . The method of  claim 1 , wherein said BMP-5 polypeptide is a human BMP-5 polypeptide. 
     
     
         10 . The method of  claim 1 , wherein said BMP-5 polypeptide comprises the amino acid sequence set forth in SEQ ID NO:1. 
     
     
         11 . A method for treating a mammal having a rotator cuff condition, wherein said method comprising administering a composition into a rotator cuff region of said mammal, wherein composition comprises cells comprising an exogenous nucleic acid encoding a BMP-5 polypeptide, wherein said cells express said BMP-5 polypeptide, and wherein administration of said composition reduces or reverses tendon degeneration, enhances tendon healing, or increases tendon strength. 
     
     
         12 . The method of  claim 11 , wherein said mammal is a human. 
     
     
         13 . The method of  claim 11 , wherein said rotator cuff condition is a rotator cuff condition wherein a rotator cuff tendon is partially torn. 
     
     
         14 . (canceled) 
     
     
         15 . The method of  claim 11 , wherein said rotator cuff condition is rotator cuff tendonitis. 
     
     
         16 - 20 . (canceled) 
     
     
         21 . A method for treating a mammal having a rotator cuff condition, wherein said method comprising administering a composition to a rotator cuff region of said mammal, wherein said composition comprises an inhibitor of SIRT6, SIRT7, or HDAC10 polypeptide expression or activity, wherein administration of said composition reduces or reverses tendon degeneration, enhances tendon healing, or increases tendon strength. 
     
     
         22 . The method of  claim 21 , wherein said mammal is a human. 
     
     
         23 . The method of  claim 21 , wherein said rotator cuff condition is a rotator cuff condition wherein a rotator cuff tendon is partially torn. 
     
     
         24 . (canceled) 
     
     
         25 . The method of  claim 21 , wherein said rotator cuff condition is rotator cuff tendonitis. 
     
     
         26 . The method of  claim 21 , wherein said administration is an intra-articular injection into a joint space. 
     
     
         27 . (canceled) 
     
     
         28 . The method of  claim 21 , wherein said administration is a direct injection into a damaged tendon. 
     
     
         29 - 32 . (canceled) 
     
     
         33 . The method of  claim 21 , wherein said composition further comprises a BMP-5 polypeptide. 
     
     
         34 . The method of  claim 21 , wherein said composition further comprises cells comprising an exogenous nucleic acid encoding a BMP-5 polypeptide, wherein said cells express said BMP-5 polypeptide.